In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Health Catalyst Inc (NASDAQ: HCAT) closed the day trading at $3.74 down -5.08% from the previous closing price of $3.94. In other words, the price has decreased by -$5.08 from its previous closing price. On the day, 0.55 million shares were traded.
Ratios:
For a better understanding of HCAT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.24. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 0.44.
On January 08, 2025, KeyBanc Capital Markets Upgraded its rating to Overweight which previously was Sector Weight but kept the price unchanged to $9.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 05 ’25 when LeSueur Daniel sold 5,209 shares for $4.10 per share. The transaction valued at 21,331 led to the insider holds 205,832 shares of the business.
LeSueur Daniel sold 5,209 shares of HCAT for $21,604 on Apr 03 ’25. The Chief Operating Officer now owns 211,041 shares after completing the transaction at $4.15 per share. On Apr 03 ’25, another insider, DANIEL LESUEUR, who serves as the Officer of the company, bought 10,418 shares for $4.45 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.84 while its Price-to-Book (P/B) ratio in mrq is 0.69.
Stock Price History:
Over the past 52 weeks, HCAT has reached a high of $9.24, while it has fallen to a 52-week low of $3.56. The 50-Day Moving Average of the stock is -9.34%, while the 200-Day Moving Average is calculated to be -41.02%.
Shares Statistics:
A total of 69.48M shares are outstanding, with a floating share count of 66.22M. Insiders hold about 4.85% of the company’s shares, while institutions hold 79.38% stake in the company.
Earnings Estimates
Its stock is currently analyzed by 10.0 different market analysts. The consensus estimate for the next quarter is $0.08, with high estimates of $0.13 and low estimates of $0.05.
Analysts are recommending an EPS of between $0.39 and $0.17 for the fiscal current year, implying an average EPS of $0.24. EPS for the following year is $0.39, with 12.0 analysts recommending between $0.59 and $0.29.
Revenue Estimates
11 analysts predict $80.8M in revenue for the current quarter. It ranges from a high estimate of $83M to a low estimate of $80.37M. As of the current estimate, Health Catalyst Inc’s year-ago sales were $75.9MFor the next quarter, 11 analysts are estimating revenue of $85.16M. There is a high estimate of $86.02M for the next quarter, whereas the lowest estimate is $84M.
A total of 13 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $335.12M, while the lowest revenue estimate was $330.1M, resulting in an average revenue estimate of $334.3M. In the same quarter a year ago, actual revenue was $306.58MBased on 13 analysts’ estimates, the company’s revenue will be $366.78M in the next fiscal year. The high estimate is $379M and the low estimate is $352.59M.
